Lei Wang

Publications

3 shown

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu , Yu-Hua Li , Xu-Hua Guan +18 more

A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID...

2020 The Lancet 1434 citations

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

Myron S. Cohen , Ying Qing Chen , Marybeth McCauley +32 more

The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such t...

2011 New England Journal of Medicine 6856 citations

Distinct mechanisms of cell in breast cancer and their clinical implication

Aodi Li , Sishi Liu , Ying Xuan +3 more

Breast cancer is a heterogeneous disease affecting women globally. Despite significant advancements in therapeutic interventions in recent years, breast cancer remains a leading...

2025 Cell Biology and Toxicology 0 citations

Researcher Info

h-index: 2
Publications: 3
Citations: 8,290
Institution: Hubei Provincial Center for Disease Control and Prevention

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-0734-7026

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.

Publications

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

Distinct mechanisms of cell in breast cancer and their clinical implication

Frequent Co-Authors

Fengcai Zhu

Yu-Hua Li

Xu-Hua Guan

Li-Hua Hou

Wen-Juan Wang

Jingxin Li

Researcher Info

External Links

Identifiers

Impact Metrics

Academic Output Over Time